FrancophonIA/ELRC3.0 huggingface dataset:
English: ♦ Very rare (less than 1 per 10,000 doses of vaccine):
Latvian: Ļoti reti (mazāk nekā 1 no 10 000 vakcīnas devām):
English: 0.5 ml in ampoule (type I glass) for 1 dose - pack size of 100
Latvian: 0,5 ml ampulā (I hidrolītiskās klases stikls) 1 devai - iepakojumā ir 100 ampulas.
English: • Itching at the injection site
Latvian: • Nieze injekcijas vietā
English: 70.8% (95% CI: 55.9;83.0)
Latvian: 70,8% (95% TI: 55,9;83,0)
English: Daronrix, suspension for injection in multidose container Pandemic influenza vaccine (whole virion, inactivated, adjuvanted)
Latvian: Daronrix, suspensija injekcijām daudzdevu konteinerā Pandēmiskās gripas vakcīna (vesels virions, inaktivēts, adsorbēts)
English: Therefore health care providers need to assess the benefits and potential risks of administering the vaccine to pregnant women taking into consideration official recommendations.
Latvian: Nav iegūti dati par Daronrix lietošanu grūtniecēm, tādēļ, lietojot vakcīnu grūtniecēm, veselības aprūpes speciālistiem, ņemot vērā oficiālos ieteikumus, jānovērtē pozitīvā ietekme un potenciālais risks.
English: VIAL (20 DOSES) X 50
Latvian: FLAKONS (20 DEVAS) X 50
English: EXPIRY DATE EXP: MM/YYYY
Latvian: DERĪGUMA TERMIŅŠ Derīgs līdz: MM/GGGG
English: Intramuscular use Shake before use
Latvian: Pirms lietošanas izlasiet lietošanas instrukciju Intramuskulārai lietošanai Pirms lietošanas sakratīt
English: * propagated in eggs ** haemagglutinin *** adjuvanted by aluminium phosphate
Latvian: *izaudzēts olās **hemaglutinīns ***adsorbents ir alumīnija fosfāts
English: MULTIDOSE PRESENTATION VIAL (10 DOSES) X 50
Latvian: MULTIDEVU IEPAKOJUMS FLAKONS (10 DEVAS) X 50
English: In this clinical study, the immunogenicity of the monovalent aluminium-adjuvanted whole virus vaccine (A/H5N1) with a haemagglutinin content of 27µg HA per dose in adults aged 18-60 years (N=49) was also evaluated following a 0, 21 day schedule.
Latvian: Šai klīniskajā pētījumā vērtēta arī monovalentas vesela vīrusa vakcīnas (A/H5N1), kurā par adjuvantu izmantots alumīnijs un hemaglutinīna daudzums ir 27 μg HA vienā devā, imunogenitāte 18 - 60 gadu veciem pieaugušiem (N=49), izmantojot 0., 21. dienas ievadīšanas shēmu.
English: What Daronrix looks like and contents of the pack
Latvian: Daronrix ārējais izskats un iepakojums
English: Daronrix, suspension for injection in pre-filled syringe Pandemic influenza vaccine (whole virion, inactivated, adjuvanted)
Latvian: Daronrix, suspensija injekcijām pilnšļircē Pandēmiskās gripas vakcīna (vesels virions, inaktivēts, adsorbēts)
English: Infections and infestations Uncommon: nasopharyngitis, rhinitis
Latvian: Infekcijas un parazitozes Retāk: nazofaringīts, rinīts
English: ♦ Rare (less than 1 per 1000 but more than 1 per 10,000 doses of vaccine):
Latvian: Reti (mazāk nekā 1 no 1000, bet vairāk nekā 1 no 10 000 vakcīnas devām):
English: 10 x 1 dose 1 dose (0.5 ml)
Latvian: 10 x 1 deva 1 deva (0,5 ml)
English: A clinical study has evaluated the immunogenicity of the monovalent aluminium-adjuvanted whole virus vaccine (A/H5N1) with a haemagglutinin content of 15 µg HA per dose in adults aged 18-60 years (N=48) following a 0, 21 day schedule.
Latvian: Klīniskā pētījumā vērtēta monovalentas, vesela vīrusa vakcīnas (A/H5N1), kurā par adjuvantu izmantots alumīnijs un hemaglutinīna daudzums ir 15 μg HA vienā devā, imunogenitāte 18 - 60 gadu veciem pieaugušiem, izmantojot 0., 21. dienas ievadīšanas shēmu.
English: ♦ Uncommon (less than 1 per 100 but more than 1 per 1000 doses of vaccine):
Latvian: Retāk (mazāk nekā 1 no 100, bet vairāk nekā 1 no 1000 vakcīnas devām):
English: 50 x 10 doses 1 dose (0.5 ml)
Latvian: 50 x 10 devas 1 deva (0,5 ml)
English: 50 x 20 doses 1 dose (0.5 ml)
Latvian: Flakons 50 x 20 devas 1 deva (0,5 ml)
English: • Swelling at the injection site, hard lump
Latvian: • Pietūkums injekcijas vietā, sacietējums
English: ♦ Common (less than 1 per 10 but more than 1 per 100 doses of vaccine):
Latvian: Bieži (mazāk nekā 1 no 10, bet vairāk nekā 1 no 100 vakcīnas devām):
English: EXPIRY DATE
Latvian: Pilnšļirce Adata
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Whole virion influenza vaccine of pandemic strain, inactivated, containing antigen* equivalent to: A/Vietnam/1194/2004 (H5N1)***
Latvian: KVALITATĪVAIS UN KVANTITATĪVAIS SASTĀVS Inaktivēta pandēmiskā celma vesela viriona gripas vakcīna, kura satur antigēnu*, kas ekvivalents šādam celmam:
English: Take special care with Daronrix:
Latvian: Īpaša piesardzība, lietojot Daronrix, nepieciešama šādos gadījumos:
English: EXP
Latvian: Ampula
English: ♦ Very common (more than 1 per 10 doses of vaccine):
Latvian: Ļoti bieži (mazāk nekā 1 no 10 vakcīnas devām):
English: Pandemic influenza vaccine should be used in accordance with official guidance.
Latvian: Pandēmiskās gripas vakcīna jālieto atbilstoši oficiālajām vadlīnijām (skatīt apakšpunktus 4.2 un 5.1).
English: GlaxoSmithKline Lietuva UAB Tel. +370 5 264 90 00 info.lt@gsk.com
Latvian: +370 5 264 90 00 info.lt@gsk.com
English: Sächsisches Serumwerk Dresden (SSW) Zirkusstraße 40
Latvian: Zirkusstraße 40
English: Vial
Latvian: Sērija
English: • Shivering, fever
Latvian: • Drebuļi, drudzis
English: • Low blood platelet count
Latvian: • Zems trombocītu skaits
English: Vasculitis with transient renal involvement.
Latvian: Vaskulīts, kas pārejoši skar arī nieres.
English: Suspension for injection Prefilled syringe 1 dose
Latvian: ZĀĻU FORMA Suspensija injekcijām Duļķaina, balta suspensija.
English: Therefore health care providers need to assess the benefits and potential risks of administering the vaccine in that population.
Latvian: Nav datu par Daronrix lietošanu pirms 18 gadu vecuma, tādēļ veselības aprūpes speciālistiem šai populācijā jāvērtē vakcinācijas pozitīvā ietekme un potenciālais risks.
English: The patient takes one capsule one hour before starting each chemotherapy cycle.
Latvian: Pacients lieto vienu kapsulu vienu stundu pirms katra ķīmijterapijas cikla sākšanas.
English: One of the active substances, palonosetron, has been authorised on its own in the EU since 2005.
Latvian: Viena no aktīvajām vielām, palonosetrons, ir atsevišķi reģistrēts ES kopš 2005. gada.
English: This is a summary of the European public assessment report (EPAR) for Akynzeo.
Latvian: Šis ir Eiropas Publiskā novērtējuma ziņojuma (EPAR) kopsavilkums par Akynzeo.
English: The full EPAR and risk management plan summary for Akynzeo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Latvian: Pilns Akynzeo EPAR teksts un riska pārvaldības plāna kopsavilkums ir atrodams aģentūras tīmekļa vietnē: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Akynzeo
Latvian: Cita informācija par Akynzeo
English: Akynzeo netupitant / palonosetron hydrochloride
Latvian: Akynzeo netupitants/palonosetrona hidrohlorīds
English: It is not intended to provide practical advice on how to use Akynzeo.
Latvian: Tas nav paredzēts kā praktiski ieteikumi par Akynzeo lietošanu.
English: What measures are being taken to ensure the safe and effective use of Akynzeo?
Latvian: Kas tiek darīts, lai nodrošinātu nekaitīgu un efektīvu Akynzeo lietošanu?
English: Why is Akynzeo approved?
Latvian: Kāpēc Akynzeo tika apstiprinātas?
English: Akynzeo is available as capsules containing 300 mg of netupitant and 0.5 mg of palonosetron.
Latvian: Akynzeo ir pieejams kā kapsulas, kas satur 300 mg netupitanta un 0,5 mg palonosetrona.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Akynzeo on 27 May 2015
Latvian: Eiropas Komisija 2015. gada 27. maijā izsniedza Akynzeo reģistrācijas apliecību, kas derīga visā Eiropas Savienībā.
English: Akynzeo contains the active substances netupitant and palonosetron.
Latvian: Akynzeo satur aktīvās vielas netupitantu un palonosetronu.
English: The most common side effects reported with Akynzeo are headache (seen in 3.6% of patients), constipation (3.0%) and fatigue (1.2%).
Latvian: Visbiežāk novērotās Akynzeo blakusparādības ir galvassāpes (novērotas 3,6 % pacientu), aizcietējumi (3,0 %) un nogurums (1,2 %).
English: Around 88% of patients taking Akynzeo experienced no vomiting on day 1 following the first chemotherapy cycle, compared with 85% of patients taking palonosetron.
Latvian: Aptuveni 88 % pacientu, kuri lietoja Akynzeo, 1. dienā pēc pirmā ķīmijterapijas cikla nebija vemšanas, salīdzinot ar 85 % pacientu, kuri lietoja palonosetronu.
English: A risk management plan has been developed to ensure that Akynzeo is used as safely as possible.
Latvian: Lai nodrošinātu iespējami nekaitīgu Akynzeo lietošanu, ir izstrādāts riska pārvaldības plāns.
English: This study involved 1,455 patients and the patients took dexamethasone, another medicine used to prevent vomiting, as an additional treatment.
Latvian: Pētījumā piedalījās 1455 pacienti, un tie kā papildu ārstēšanu lietoja deksametazonu, citas zāles, ko lieto vemšanas profilaksei.
English: The figures for day 2 to day 5 were 77% for patients in the Akynzeo group and 70% for those in the palonosetron group.
Latvian: 2. līdz 5. dienā Akynzeo grupā tie bija 77 % pacientu un 70 % palonosetrona grupā.
English: receptors, which are found in the nervous system and are responsible for the delayed phase of nausea and vomiting (that occurs after the first 24 hours); palonosetron, on the other hand, blocks 5HT3 receptors in the gut, which are responsible for the immediate phase (that occurs within the first 24 hours).
Latvian: (NK1) receptorus, kas atrodas nervu sistēmā un atbild par sliktas dūšas un vemšanas aizkavēto fāzi (pēc pirmajām 24 stundām); palonosetrons, no otras puses, kuņģī bloķē 5HT3 receptorus, kas atbild par akūto fāzi (pirmajās 24 stundās).
English: Netupitant works by blocking neurokinin-1 (NK1)
Latvian: Netupitants iedarbojas, bloķējot neirokinīna 1
English: For practical information about using Akynzeo, patients should read the package leaflet or contact their doctor or pharmacist.
Latvian: Lai iegūtu praktisku informāciju par Akynzeo lietošanu, pacientiem jāizlasa zāļu lietošanas instrukcija vai jāsazinās ar ārstu vai farmaceitu.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) noted that Akynzeo was effective at preventing both the immediate and delayed phases of nausea and vomiting following chemotherapy, and that the medicine has a favourable safety profile.
Latvian: Aģentūras Cilvēkiem paredzēto zāļu komiteja (CHMP) nolēma, ka Akynzeo efektīvi novērš gan akūto, gan aizkavēto sliktas dūšas un vemšanas fāzi pēc ķīmijterapijas un ka zālēm ir labvēlīgs drošuma profils.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Akynzeo, including the appropriate precautions to be followed by healthcare professionals and patients.
Latvian: Pamatojoties uz šo plānu, Akynzeo zāļu aprakstā ir ietverta drošuma informācija, kā arī lietošanas instrukcija, tostarp attiecīgi piesardzības pasākumi, kas jāievēro veselības aprūpes speciālistiem un pacientiem.
English: In a main study comparing Akynzeo with palonosetron alone, 90% of patients taking Akynzeo (121 out of 135) experienced no vomiting within 5 days of starting highly emetogenic chemotherapy compared with 77% of patients taking palonosetron alone (104 out of 136).
Latvian: Pamatpētījumā, Akynzeo salīdzinot ar atsevišķi lietotu palonosetronu, 90 % pacientu, kuri lietoja Akynzeo (121 no 135) 5 dienas pēc izteikti emetogēnas ķīmijterapijas sākšanas nebija vemšanas, salīdzinot ar 77 % pacientu, kuri lietoja tikai palonosetronu (104 no 136).
English: The Committee therefore concluded that the medicine's benefits are greater than its risk and recommended that it be approved for use in the EU.
Latvian: Tādēļ Komiteja nolēma, ka pacientu ieguvums, lietojot Akynzeo, pārsniedz šo zāļu radīto risku, un ieteica izsniegt šo zāļu reģistrācijas apliecību.
English: The two active substances in Akynzeo work by blocking two different mechanisms involved in inducing nausea and vomiting during chemotherapy.
Latvian: Akynzeo divas aktīvās vielas iedarbojas, bloķējot divus dažādus mehānismus, kas iesaistīti sliktas dūšas un vemšanas ierosināšanā ķīmijterapijas laikā.
English: A second main study looked at the benefits of Akynzeo in patients undergoing moderately emetogenic chemotherapy.
Latvian: Otrajā pamatpētījumā pētīja Akynzeo ieguvumus pacientiem, kuri saņem vidēji emetogēnu ķīmijterapiju.
English: For more information about treatment with Akynzeo, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Latvian: Plašāka informācija par ārstēšanu ar Akynzeo ir atrodama zāļu lietošanas instrukcijā (kas arī ir EPAR daļa) vai sazinoties ar ārstu vai farmaceitu.
English: What is Akynzeo and what is it used for?
Latvian: Kas ir Akynzeo un kāpēc tās lieto?
English: Some chemotherapy is known to induce severe nausea and vomiting, and Akynzeo is used in patients receiving either highly emetogenic (vomit-inducing) chemotherapy based on the cancer medicine cisplatin, or other chemotherapies that are moderately emetogenic.
Latvian: Zināms, ka dažas ķīmijterapijas zāles izraisa smagu sliktu dūšu un vemšanu, un Akynzeo lieto pacientiem, kuri saņem vai nu izteikti emetogēnu (vemšanu ierosinošo) ķīmijterapiju, kuras pamatā ir pretvēža zāles cisplatīns, vai citas vidēji emetogēnas ķīmijterapijas zāles.
English: Akynzeo is a medicine used to prevent nausea (feeling sick) and vomiting in adult patients with cancer who are receiving chemotherapy (medicines to treat cancer).
Latvian: Akynzeo ir zāles, ko lieto, lai profilaktiski novērstu sliktu dūšu un vemšanu pieaugušiem pacientiem ar vēzi, kuri saņem ķīmijterapiju (pretvēža zāles).
English: How is Akynzeo used?
Latvian: Kā lieto Akynzeo?
English: By having both active substances together, Akynzeo helps provide control for both the immediate and delayed phases of nausea and vomiting than occur following chemotherapy.
Latvian: Apvienojot abas aktīvās vielas, Akynzeo nodrošina pēc ķīmijterapijas notiekošās gan akūtās, gan aizkavētās fāzes kontroli.
English: What benefits of Akynzeo have been shown in studies?
Latvian: Kādas bija Akynzeo priekšrocības šajos pētījumos?
English: What are the risks associated with Akynzeo?
Latvian: Kāds risks pastāv, lietojot Akynzeo?
English: How does Akynzeo work?
Latvian: Kā Akynzeo darbojas?
English: Pack size
Latvian: Tiešais iepak ojums
English: MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administra
Latvian: Stiprums Zāļu forma
English: Kruczkowskiego 8 00-380 Warzawa Poland
Latvian: Kruczkowskiego 8 00-380 Warszawa Poland
English: Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the member states
Latvian: I PIELIKUMS ZĀĻU NOSAUKUMI, ZĀĻU FORMAS, STIPRUMI, LIETOŠANAS VEIDS, REĢISTRĀCIJAS APLIECĪBAS ĪPAŠNIEKI DALĪBVALSTĪS
English: Piazzale dell'Industria, 20 00144 Roma
Latvian: Piazzale dell'Industria, 20 00144 Roma Italy
English: A- 1221 Vienna Austria
Latvian: 1221 Vienna
English: Czech Republic Baxter Czech spol.
Latvian: Baxter Czech spol.
English: Norfork IP24 3SE, United Kingdom
Latvian: Norfolk IP24 3SE, United Kingdom
English: Baxter Médico-Farmacêutica, Lda.
Latvian: Médico-Farmacêutica, Lda.
English: The Netherlands Baxter AG Industriestraße 67
Latvian: Luksemburga Baxter AG Industriestraße 67
English: ARTISS soluciones para adhesivo tisular
Latvian: ARTISS soluciones para adhesivo tisular Ultracongeladas
English: Baxter Medical AB, Isafjordstgatan 30B P.O.
Latvian: Baxter Medical AB, Isafjordsgatan 30B P.O.
English: BERIPLAST P 0.5 ml, 1 ml, 3 ml, powders and solvents for sealant Combi-Set
Latvian: BERIPLAST P 0.5 ml, 1 ml, 3 ml, powders and solvents for sealant
English: Karla Engliše 3201/6
Latvian: Karla Engliše 3201/6 150 00 Praha 5
English: Zona Industrial da Abrunheira - Edifício 10 - Sintra Business Park
Latvian: Zona Industrial da Abrunheira - Edifício 10Sintra Business Park 2710-089 Sintra Portugal
English: Beriplast and associated names Member State (in EEA)
Latvian: Beriplast un sinonīmiskie nosaukumi Dalībvalsts (EEZ teritorijā)
English: Polígono Industrial Sector 14 Pouet de Camilo, 2
Latvian: Pouet de Camilo, 2
English: TISSEEL Lyo, TwoComponent Fibrin Sealant
Latvian: TISSEEL Lyo, Two-Component Fibrin Sealant
English: Component 2
Latvian: 2. komponents
English: Beriplast P CombiSet Pulver und Lösungsmittel für einen
Latvian: Beriplast P Combi-Set Pulver und Lösungsmittel für einen Gewebekleber
English: Component Fibrin Sealant
Latvian: Two-component Fibrin Sealant
English: Beriplast P CombiSet 0,5ml/1ml/3ml
Latvian: Beriplast P Combi-Set 0,5ml/1ml/3ml
English: Beriplast P CombiSet 1 ml prašek in vehikel za lepilo za tkiva
Latvian: Combi-Set 1 ml prašek in vehikel za lepilo za tkiva
English: Beriplast P CombiSet 3 ml prašek in vehikel za lepilo za tkiva
Latvian: Combi-Set 3 ml prašek in vehikel za lepilo za tkiva
English: Intralesional use
Latvian: Lietošanai bojājumā
English: Combi-Set 2: thrombin: 500 IU/ml
Latvian: Combi-Set 2: Trombīns : 500 IU/ml
English: Component 1
Latvian: 1. komponents
English: Tisseel - Lösungen für einen
Latvian: Tisseel - Lösungen für einen Gewebekleber
English: The Netherlands Baxter B.V. Kobaltweg 49, Utrecht 3542 CE
Latvian: Kobaltweg 49, 3542 CE Utrecht The Netherlands
English: Tisseel Lyo - Pulver und Lösungsmittel für einen
Latvian: Tisseel Lyo - Pulver und Lösungsmittel für einen Gewebekleber
English: Norfork
Latvian: Norfolk
English: ARTISS - Lösungen für einen
Latvian: ARTISS - Lösungen für einen Gewebekleber
English: Artiss and associated names; Tisseel and associated names; Tissucol and associated names Member State (in EEA)
Latvian: Tissucol un sinonīmiskie nosaukumi Dalībvalsts (EEZ teritorijā)
English: Baxter Hungary Kft. Népfürdő u. 22.
Latvian: Népfürdő u. 22. IX. em.
English: Calcium chloride: 40 µmol/ml
Latvian: Kalcija hlorīds: 40 μmol/ml
English: Thrombin: 500 IU/ml Calcium chloride: 5,9 mg/ml
Latvian: Trombīns : 500 IU/ml Kalcija hlorīds: 5,9 mg/ml
English: Fibrinogen human 90,00 mg /ml Factor XIII : 10,00 UI/ml Fibronectin : 5,50 mg/ml Plasminogen : 0,08 mg/ml Aprotinin 3000,0 UIK*** /ml
Latvian: Cilvēka fibrinogēns: 90,00 mg/ml XIII faktors: 10,00 SV/ml Fibronektīns: 5,50 mg/ml Plazminogēns: 0,08 mg/ml Aprotinīns: 3000,0 KIV***/ml
English: Plasmafibrinonectinum 5,5mg/ml Factor XIII coagulationis humanus 30
Latvian: Plazmas fibronektīns: 5,5 mg/ml Cilvēka XIII koagulācijas faktors: 30 SV/ml
English: 150 00 Praha 5
Latvian: Tissucol Duo 500
English: Beriplast P CombiSet 0,5 ml, Beriplast P CombiSet 1 ml,
Latvian: Beriplast P Combi-Set 0,5 ml, Beriplast P Combi-Set 1 ml, Beriplast P Combi-Set 3 ml
English: TISSUCOL Kit 1,0 kétkomponensű fibrinragasztó
Latvian: Kit 1,0 kétkomponensű fibrinragasztó
English: Thrombin (human) 500 I.E./ml Calcium chloride: 5,88 mg/ml
Latvian: Trombīns (cilvēka): 500 SV/ml Kalcija hlorīds: 5,88 mg/ml
English: Aprotinin: 3000 KIU/ml Thrombin: 500 IU/ml Calcium chloride: 40 μmol/ml
Latvian: Aprotinīns: 3000 KIV/ml Trombīns: 500 SV/ml Kalcija hlorīds: 40 μmol/ml
English: TISSUCOL Kit 2,0 kétkomponensű fibrinragasztó
Latvian: Kit 2,0 kétkomponensű fibrinragasztó
English: TISSUCOL Kit 5,0 kétkomponensű fibrinragasztó
Latvian: Kit 5,0 kétkomponensű fibrinragasztó
English: Human fibrinogen: 90 mg Coagulation factor XIII: 60 UI Aprotinin: 1000 KUI Trombin: 7,6 mg Calcium chloride: 5,9 mg
Latvian: Cilvēka fibrinogēns: 90 mg XIII koagulācijas faktors: 60 UI Aprotinīns : 1000 KUI Trombin: 7,6 mg Kalcija hlorīds: 5,9 mg
English: Thrombin S lyophilized: 500 I.E/ml Thrombin L lyophilized: 4 I.E/ml Calcium chloride: 5,88 mg/ml
Latvian: Liofilizēts S trombīns: 500 SV/ml Liofilizēts L trombīns: 4 SV/ml Kalcija hlorīds: 5,88 mg/ml
English: UI/ml; Plasminogen 0.04-0.12 mg/ml;
Latvian: XIII faktors: 10-50 V/ml Plazminogēns: 0,04-0,12 mg/ml
English: Tisseel duo quick Plasmaproteinum humanum 100-130 mg/ml: Fibrinogen 90mg/ml
Latvian: Cilvēka plazmas proteīns - 100130 mg/ml: fibrinogēns90 mg/ml
English: 2nd Component: Thrombin 500 UI/ml
Latvian: 2. komponents Trombīns: 500 SV/ml
English: Fibrinogen: 90 mg/ml Coagulation factor XIII: 60 U/ml Aprotinin: 1000 KIU/ml=0.56 PEU/ml
Latvian: Fibrinogēns: 90 mg/ml XIII koagulācijas faktors: 60 U/ml Aprotinīns: 1000 KIU/ml=0.56 PEU/ml
English: Thrombin 500 IU or Thrombin 4 UI; Calcium Chlorid Dihydrate 5.88 mg
Latvian: 500 SV trombīna vai 4 SV trombīna Kalcija hlorīda dihidrāts: 5,88 mg
English: CHLORIDE: Proteins 50mg/ml; Thrombin 500 UI/ml; calcium chloride 40 µmol/ml
Latvian: TROMBĪNA-KALCIJA HLORĪDA šļirce: proteīni - 50 mg/ml; trombīns - 500 SV/ml; kalcija hlorīds - 40 µmol/ml
English: Bottle 1: Total Proteins 100-130 mg/ml; dont clottable protein 75-115 mg/ml, Factor XIII 10-50 UI/ml; Plasminogen 0.04-0.12 mg/ml; Bottle 2: Aprotinin bovine 3000 UIK/ml (1.67 UPE/ml);
Latvian: 1. pudele: kopējie proteīni - 100130 mg/m, no kuriem recēšanas proteīns - 75-115 mg/ml, XIII faktors - 10-50 SV/ml; plazminogēns - 0,04-0,12 mg/ml; 2. pudele: vērša aprotinīns3000 KIV/ml (1,67 EPU/ml);
English: Powder and solvent for tissue sealant
Latvian: Pulveris un šķīdumi sīlanta pagatavošanai
English: Clottable protein: 375-575 mg, thereof Fibrinogen 350-550 mg; Plasma Fibronectin 10-45 mg; Factor XIII 50-250 UI;
Latvian: Kopējie proteīni: 500-650 mg Recēšanas proteīns: 375-575 mg, no kura fibrinogēns - 350550 mg/ml
English: Proteins 50mg/ml; Bottle 4: Human Thrombin 4 UI/ml; Proteins 50mg/ml;
Latvian: 3. pudele: cilvēka trombīns500 SV/ml; proteīni - 50 mg/ml; 4. pudele: cilvēka trombīns4 SV/ml; proteīni - 50 mg/ml; 5. pudele: kalcija hlorīds40 µmol/ml
English: ARTISS LYOPulver und Lösungsmittel für einen
Latvian: ARTISS LYO - Pulver und Lösungsmittel für einen Gewebekleber
English: Human fibrinogen: 90 mg/ml Coagulation factor XIII: 60 e/ml Aprotinin: 1000 EIK/ml Thrombin: 7,6 mg/ml Calcium chloride: 5,9 mg/ml
Latvian: Cilvēka fibrinogēns: 90 mg/ml XIII koagulācijas faktors: 60 e/ml Aprotinīns : 1000 EIK/ml Trombīns : 7,6 mg/ml Kalcija hlorīds: 5,9 mg/ml
English: Syringe TISSUCOL-APROTININ: Total Proteins 100-130 mg/ml; clottable protein 75-115 mg/ml, of which fibrinogen 70-110 mg/ml and plasmatic fibronectin 2-9 mg/ml: Factor XIII 10-50 UI/ml; Plasminogen 0.04-0.12 mg/ml; Aprotinin 3000 UIK/ml (1.67 UPE/ml); Syringe THROMBIN-CALCIUM CHLORIDE: Proteins 50mg/ml; Thrombin 500 UI/ml; calcium chloride 40 µmol/ml
Latvian: TISSUCOL-APROTINĪNA šļirce: kopējie proteīni - 100-130 mg/ml; recēšanas proteīns - 75115 mg/ml, no kura fibrinogēns 70110 mg/ml un plazmas fibronektīns 2-9 mg/ml; XIII faktors - 1050 SV/ml; plazminogēns - 0,040,12 mg/ml; aprotinīns3000 KIV/ml (1,67 EPU/ml);
English: Fibrinogen: 70 - 110 mg/ml Fibronectine 2 - 9 mg/ml Thrombin: 500 IU/ml Calcium chloride: 40 µmol/ml Factor XIII: 10 - 50 IU/ml Aprotinine (bovine): 3000 KIU/ml
Latvian: Fibrinogēns: 70-110 mg/ml Fibronektīns: 2-9 mg/ml Trombīns: 500 SV/ml Kalcija hlorīds: 40 μmol/ml XIII faktors: 10-50 SV/ml Aprotinīns (vērša): 3000 KIV/ml
English: Fibrinogen 72-110 mg/ml Factor XIII coagulationis humanus 10 IU/ml
Latvian: Fibrinogēns: 72-110 mg/ml Cilvēka XIII koagulācijas faktors: 10 SV/ml
English: Fibrinogen: 90 mg/ml Coagulation factor XIII: 60 U/ml Aprotinin: 1000 KIU = 0,56 EPU Thrombin: 500 IU /ml Calcium chloride (dihydrate): 5,9 mg/ml
Latvian: Fibrinogēns: 90 mg/ml XIII koagulācijas faktors: 60 U/ml Aprotinīns : 1000 KIU = 0,56 EPU Trombīns : 500 IU /ml Kalcija hlorīda dihidrāts: 5,9 mg/ml
English: Fibrinogen: 90 mg/ml Aprotinin (bovine): 1000 KIU/ml Thrombin: 500 IU/ml Calcium chloride: 5,9 mg/ml Factor XIII: 60 U/ml
Latvian: Fibrinogēns: 90 mg/ml Aprotinīns (vērša): 1000 KIU/ml Trombīns : 500 IU/ml Kalcija hlorīds: 5,9 mg/ml Factor XIII: 60 U/ml
English: Fibrinogen: 70-110mg/ml Plasmafibronectin (CIG): 2-9mg/ml Factor XIII: 10-50 U/ml Plasminogen: 0.04 - 0.12mg/ml
Latvian: Fibrinogēns: 70-110 mg/ml Plazmas fibronektīns: 2-9 mg/ml XIII koagulācijas faktors: 1050 SV/ml
English: Fibrinogen: 72-110mg/ml Aprotinin: 3000KIU/ml Thrombin: 500 IU/ml in 45-55mg total protein
Latvian: Fibrinogēns: 72-110 mg/ml Aprotinīns: 3000 KIV/ml Trombīns: 500 SV/ml kopējā 4555 mg proteīnu daudzumā Kalcija hlorīds: 40 μmol/ml